Synthekine, Inc.

Robert Kastelein

Deepti Rokkam

Patrick J Lupardus

Sandro Vivona

Mahalakshmi Ramadass

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human gp130, compositions comprising such antibodies, and methods of use thereof.

GP130 binding molecules and methods of use

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL10Ra, compositions comprising such antibodies, and methods of use thereof.

IL10RA binding molecules and methods of use

Provided herein are IL12R binding molecules that bind to IL12Rb1 and IL12Rb2 and comprise an anti-IL12Rb2 sdAb and an anti-IL12Rb2 VH antibody.

IL12 receptor synthetic cytokines and methods of use

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL10Rb, compositions comprising such antibodies, and methods of use thereof.

IL10RB binding molecules and encoding nucleic acids

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of IL2Rb, compositions comprising such antibodies, and methods of use thereof.

IL2RB binding molecules and methods of use

Provided herein are IL27R binding proteins that bind to IL27Rα and gp130 and comprise an anti-IL27Rα VH antibody and an anti-gp130 VH antibody.

Compositions and methods related to IL27 receptor binding

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL27Rα, compositions comprising such antibodies, and methods of use thereof.

IL27RAlpha binding molecules and methods of use

Provided herein are IL10R binding molecules that bind to IL10Ra and IL10Rb and comprise an IL10Rb sdAb and an IL10Rb VHH antibody.

IL10 receptor binding molecules and methods of use

Provided herein are IFNGR binding molecules that bind to IFNGR1 and IFNGR2 and comprise an anti-IFNGR2 sdAb and an anti-IFNGR2 VH antibody.

IFNGR binding synthetic cytokines and methods of use

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL2Rg, compositions comprising such antibodies, and methods of use thereof.

IL2RG binding molecules and methods of use

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IFNgR2, compositions comprising such antibodies, and methods of use thereof.

Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL23R, compositions comprising such antibodies, and methods of use thereof. Further disclosed are sequences of complementarity determining regions (CDR1, CDR2 and CDR3) and polypeptide sequences of human and mouse sdAbs.

IL23R binding molecules and methods of use

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human 1LI2RM, compositions comprising such antibodies, and methods of use thereof.

Growing community of inventors

Menlo Park, CA, United States of America

Robert Kastelein